Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs

Zhang, T; Forde, PM; Sullivan, RJ; Sharon, E; Barksdale, E; Selig, W; Ebbinghaus, S; Fusaro, G; Gunenc, D; Battle, D; Burns, R; Hurlbert, MS; Stewart, M; Atkins, MB

Zhang, T (通讯作者),UT Southwestern, Dept Internal Med, Div Hematol & Oncol, Dallas, TX 75390 USA.

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023; 11 (5):

Abstract

With multiple PD-(L)1 inhibitors approved across dozens of indications by the US Food and Drug Administration, the number of patients exposed to these......

Full Text Link